GSK (NYSE:GSK) (LON:GSK) said on Monday that the U.S. Food and Drug Administration has accepted its priority review ...

GSK tops Q2 estimates with growth in vaccines and specialty drugs, raises 2025 forecast amid progress in major late-stage pipeline assets.

With a portfolio of 14 potential blockbuster treatments that it expects to launch over the next five years, GSK is sticking to its projection to generate sales of more than 40 billion pounds sterling ...

In exchange, Hengrui will receive $500m in upfront fees and will be eligible for approximately $12bn in development, ...

British drugmaker GSK said on Monday that the U.S. Food and Drug Administration has accepted its application for priority ...

Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

SALES FORECAST: The U.K. pharmaceutical company is expected to report sales of 7.8 billion pounds ($10.42 billion), according to consensus estimates compiled by the company. For last year's second ...

The pharma giant will also receive a 1% royalty on future U.S. sales of influenza, Covid-19 and other related combination ...

Arab Finance: GlaxoSmithKline Egypt (GSK–Egypt) logged consolidated net profits for controlling interest of EGP 65.060 ...

GSK Egypt posted non-consolidated net profits after tax of EGP 71.33 million in H1-25, an annual drop from EGP 99.54 million. Meanwhile, the EPS declined to EGP 0.85 from EGP 1.19. In April-June 2025, ...

GSK’s share price is still significantly down on the year, despite very robust H1 results, leaving it looking extremely ...

GSK does have some important weaknesses as an investment vehicle, however. Chief among them is the lack of a clear-cut all-star in areas like cancer, rare diseases, or metabolic disorders.